SCHEMBL8844762

SCHEMBL8844762

COc1ccc(Oc2ccccc2)cc1C=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.59
TTR P02766 2/20 0.58
ALDH1A1 P00352 8/20 0.54
LMNA P02545 3/20 0.54
CYP1A2 P05177 2/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
KMT2A Q03164 4/20 0.51
GAA P10253 2/20 0.51
TUBB1 Q9H4B7 1/20 0.51
LTA4H P09960 1/20 0.50
KDM4E B2RXH2 4/20 0.47
TDP1 Q9NUW8 2/20 0.47
TSHR P16473 1/20 0.47
MAPT P10636 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
GLA P06280 1/20 0.46
HPGD P15428 1/20 0.46
MEN1 O00255 3/20 0.46
ALOX12 P18054 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25642257 0.87 TUBB1 (0.51) ERN1TTRALDH1A1LMNACYP1A2
SCHEMBL28451899 0.87 ALDH1A1 (0.69) ERN1TTRALDH1A1LMNACYP1A2
SCHEMBL26705583 0.85 TUBB1 (0.50) ERN1TTRALDH1A1LMNACYP1A2
SCHEMBL9049946 0.85 NFE2L2 (0.55) ERN1TTRALDH1A1LMNACYP1A2
SCHEMBL29392394 0.82 ALDH1A1 (0.71) ERN1ALDH1A1CYP1A2TUBB1KDM4E
SCHEMBL172939 0.82 ALDH1A1 (0.71) ERN1ALDH1A1CYP1A2TUBB1KDM4E
SCHEMBL11123319 0.81 ALDH1A1 (0.53) ERN1TTRALDH1A1LMNACYP1A2
SCHEMBL31287740 0.81 TUBB1 (0.49) ERN1ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL24515546 0.80 ERN1 (0.54) ERN1TTRALDH1A1LMNAKMT2A
SCHEMBL14451771 0.80 TLR9 (0.61) ERN1ALDH1A1LMNAKMT2ATUBB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS ELI LILLY AND COMPANY 2024-01-18 US disclosed
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS ELI LILLY AND COMPANY 2024-01-18 US disclosed
US-11787834-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2023-10-17 US disclosed
US-11787834-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2023-10-17 US disclosed
US-5602151-A ADMINISTERING TO MAMMALS TO REDUCE SERUM CHOLESTEROL LEVELS AMERICAN HOME PRODUCTS CORPORATION (US) 1997-02-11 US disclosed
US-5512565-A REDUCE CHOLESTEROL ABSORPTION IN MAMMALS AMERICAN HOME PRODUCTS CORPORATION (US) 1996-04-30 US disclosed
US-5391571-A Cholesterol ester hydrolase inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 1995-02-21 US disclosed
EP-0428385-A1 Cholesterol ester hydrolase inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 1991-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R ERN1 1650/4885TTR 2824/4885ALDH1A1 3227/4885
US-11787834-B2 Glucocorticoid receptor agonists NR3C1, NR3C2, MC2R ERN1 1650/4885TTR 2824/4885ALDH1A1 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.